Morton

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.

Researchers are evaluating the effects of KAI-9531, given by weekly subcutaneous injection, compared to a placebo in adults living with obesity who do not have diabetes. This Phase 2b study aims to determine how KAI-9531 impacts body weight over time, specifically measuring the percent change from baseline to week 48. Participants will receive either KAI-9531 or a placebo via subcutaneous injection once a week during the study. The study is randomized, double-blind, and placebo-controlled to ensure reliable comparison between the treatment and placebo groups. The main treatment period lasts 48 weeks. During the study, participants will have their body weight measured at baseline and at week 48 to assess changes. Researchers will monitor safety and efficacy throughout the treatment period. The total participation time includes the treatment period and any necessary follow-up visits to track outcomes and ensure participant well-being.